Clinical trial · Interventional
Biobanking and New Biomolecular Metrics
Melanoma 4p: Biobanking and New Biomolecular Metrics
NCT05906277CI-TRIAL-00067146Melamoma4punknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this Interventional study aims to apply, in our Institutes, a 4p oncological model i.e. predictive, personalized, of precision and participated (Regina Elena and San Gallicano).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liquid Biopsy | — | UNRESOLVED | — |
| Melanoma (Skin) | Melanoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Biopsy | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (4)
- measure
- Oncology target therapy
- timeFrame
- 12 months
- description
- Integration between molecular diagnostic and melanoma histopathology: correlation between mutational miRNA/ncRNA profiles and pathological staging parameters.
- measure
- Oncology target therapy
- timeFrame
- 12 months
- description
- Correlation between molecular diagnostic and imaging non-invasive instrumental diagnostic
- measure
- Oncology target therapy
- timeFrame
- 12 months
- description
- Correlation between molecular diagnostic and dermatologic clinical diagnostic; integration of liquid biopsy during oncologic ambulatorial follow-up; lead time of relapse.
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Melanoma affected patients Exclusion Criteria: * No patiens affected by other pathology
References
Publications (0)
Data not yet available
No reference posted for this study.